RNA interference with zilebesiran for mild to moderate hypertension: the KARDIA-1 Randomized Clinical Trial

GL Bakris, M Saxena, A Gupta, F Chalhoub, J Lee… - JAMA, 2024 - jamanetwork.com
Importance Angiotensinogen is the most upstream precursor of the renin–angiotensin–
aldosterone system, a key pathway in blood pressure (BP) regulation. Zilebesiran, an …
被引用次数：15 相关文章

RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial.

GL Bakris, M Saxena, A Gupta… - JAMA: Journal of …, 2024 - search.ebscohost.com
Abstract Key Points: Question: Does targeting hepatic angiotensinogen synthesis with the
RNA interference therapeutic zilebesiran reduce blood pressure in adults with mild to …

RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial

GL Bakris, M Saxena, A Gupta, F Chalhoub, J Lee… - …, 2024 - pubmed.ncbi.nlm.nih.gov
Importance Angiotensinogen is the most upstream precursor of the renin-angiotensin-
aldosterone system, a key pathway in blood pressure (BP) regulation. Zilebesiran, an …
[PDF] japic.or.jp

[PDF][PDF] JAPIC Pharma Report

GL Bakris - JAMA The Journal of the American Medical Association, 2024 - japic.or.jp
✓ 抄録やキーワードをご覧になりたい場合には, 弊センター提供の iyakuSearch
などのデータベースをご覧ください.[複写申込みについて] JAPIC ホームページ内 (https://www …

RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial.

GL Bakris, M Saxena, A Gupta, F Chalhoub, J Lee… - JAMA, 2024 - europepmc.org
RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1
Randomized Clinical Trial. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …